Más allá del receptor de dopamina: Nuevos blancos terapéuticos para tratar la esquizofrenia

Translated title of the contribution: Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia

Joseph T. Coyle, Darrick Balu, Michael Benneyworth, Alo Basu, Alexander Roseman

Research output: Contribution to journalArticlepeer-review

60 Scopus citations

Abstract

All current drugs approved to treat schizophrenia appear to exert their antipsychotic effects through blocking the dopamine D2 receptor. Recent meta-analyses and comparative efficacy studies indicate marginal differences in efficacy of newer atypical antipsychotics and the older drugs, and little effects on negative and cognitive symptoms. This review integrates findings from postmortem, imaging, and drug-challenge studies to elucidate a corticolimbic "pathologic circuit" in schizophrenia that may be particularly relevant to the negative symptoms and cognitive impairments of schizophrenia. Potential sites for pharmacologic intervention targeting glutatatergic, GABAergic, and cholinergic neurotransmission to treat these symptoms of schizophrenia are discussed.

Translated title of the contributionBeyond the dopamine receptor: novel therapeutic targets for treating schizophrenia
Original languageSpanish
Pages (from-to)359-382
Number of pages24
JournalDialogues in Clinical Neuroscience
Volume12
Issue number3
StatePublished - 2010

Keywords

  • Glutamate
  • Metabotropic glutamate receptor
  • N-methyl-D-aspartate receptor
  • Nicotinic acetylcholine receptor
  • γ-aminobutyric acid

Fingerprint Dive into the research topics of 'Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia'. Together they form a unique fingerprint.

Cite this